Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eahMCfbwoceTubsJuwhG

November 20, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • FDA expands approval of GSK-Ligand's platelet drug Promacta
    The FDA approved GlaxoSmithKline and Ligand Pharmaceuticals' Promacta, or eltrombopag, to treat low platelet count in people with hepatitis C, so they can receive standard treatment. The approval is the first for supportive care to help patients unsuited for interferon-based therapy because of low platelet counts. Reuters (11/19) LinkedInFacebookTwitterEmail this Story
Complimentary Webinar - Simplifying the Audit Management Process
Tuesday, November 27, 2012, 11:00 am Eastern
Join us to hear how the new TrackWise Audit Execution Package Bundle drives efficiency through enhanced TrackWise capabilities, advanced services and training. Learn how the TrackWise Audit Execution Package can improve productivity, reduce costs and streamline your audit processes in the most effective manner. Register Now!
  Health Care & Policy 
  • Celgene's myeloma drug pomalidomide improves survival in trial
    Patients with multiple myeloma who received Celgene's pomalidomide plus low-dose dexamethasone lived significantly longer and had greater progression-free survival than those who received high-dose dexamethasone alone during a trial. An FDA review of the drug is expected to be completed by Feb. 10. Reuters (11/19) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Global Developments 
  • Living Cell Technologies to start human Ntcell trial
    New Zealand's health regulators have given the go-ahead for Living Cell Technologies' early-stage clinical study of its Ntcell treatment for Parkinson's disease. The first human trial for the treatment is slated to start early next year. The therapy includes the transplantation of animal choral plexus cells into the brain to restore nerves. Australian Life Scientist (11/16) LinkedInFacebookTwitterEmail this Story
  Food & Agriculture 
  Industrial & Environmental 
  • BIO hails EPA's decision to deny RFS waiver requests
    BIO and other ethanol groups praised the Environmental Protection Agency's decision to reject the requests for a temporary waiver of the Renewable Fuel Standard. The decision to uphold RFS would protect the country's energy security and support advances in commercializing production of advanced biofuels, said BIO Executive Vice President Brent Erickson. "This decision allows BIO member companies to continue to deliver innovative technologies to the market to expand our domestic production of biofuels, including fuels from agricultural residues, municipal solid waste, algae and purpose grown energy crops," he said. EthanolProducer.com (11/16) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • Are you taking full advantage of your membership?
    BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
A good man with a good conscience doesn't walk so fast."
--Georg Büchner,
German writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information